Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 6,151 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Breast cancer Clear all
Completed Phase 1Phase 2 Interventional

Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

NCT00070252
View directory record Official record
Conditions
Adult Solid Neoplasm, Inflammatory Breast Carcinoma, Male Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
Capecitabine, Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study, Tipifarnib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
7
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 6, 2026, 2:46 PM EDT
Active, not recruiting Phase 2 Interventional

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

NCT04647916
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Sacituzumab Govitecan
Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
296
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 210 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 6, 2026, 2:46 PM EDT
Completed Phase 3 Interventional

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

NCT00003906
View directory record Official record
Conditions
Breast Cancer
Interventions
Raloxifene, Tamoxifen
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
35 Years and older · Female only
Enrollment
19,747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
492
States / cities
Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 369 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 6, 2026, 2:46 PM EDT
Recruiting Phase 1 Interventional

HER-2 B Cell Peptide Vaccine

NCT06414733
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2-positive Breast Cancer, EGFR Overexpression, Metastatic Esophageal Carcinoma, HER-2 Positive Esophageal Cancer
Interventions
Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 51
Biological
Lead sponsor
Pravin T.P Kaumaya
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Indianpolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 6, 2026, 2:46 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

NCT00019084
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
aldesleukin, mutant p53 peptide pulsed dendritic cell vaccine, ras peptide cancer vaccine, sargramostim, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 6, 2026, 2:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

NCT01104584
View directory record Official record
Conditions
Breast Cancer
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Tucson, Arizona • Oakland, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2014 · Synced Oct 6, 2026, 2:46 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer

NCT00003352
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, Taxotere, Adriamycin
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
152
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 120 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 6, 2026, 2:46 PM EDT
Not listed Not applicable Interventional

Post-Mastectomy Surveillance to Detect Recurrence in Breast Cancer Patients

NCT02688725
View directory record Official record
Conditions
Breast Cancer
Interventions
post mastectomy ultrasound
Device
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Everett, Washington
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 6, 2026, 2:46 PM EDT
Completed Phase 2 Interventional

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

NCT03113825
View directory record Official record
Conditions
Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer
Interventions
Investigational Imaging device, AVB-620
Device · Drug
Lead sponsor
Avelas Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 6, 2026, 2:46 PM EDT
Terminated Phase 2 Interventional Results available

Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer

NCT00777335
View directory record Official record
Conditions
Breast Cancer
Interventions
Panobinostat - LBH589
Drug
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 6, 2026, 2:46 PM EDT
Completed Not applicable Interventional

Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity

NCT02566408
View directory record Official record
Conditions
Cancer Survivor, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
One-on-one interview, Survey Questions
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
65 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 6, 2026, 2:46 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425
View directory record Official record
Conditions
Advanced or Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Capecitabine, Paclitaxel, Nab-Paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 105 Years
Enrollment
866 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Scottsdale, Arizona • Springdale, Arkansas • Duarte, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 6, 2026, 2:46 PM EDT
Completed Phase 2 Interventional Results available

Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer

NCT00077376
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
trastuzumab, ixabepilone, carboplatin, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 6, 2026, 2:46 PM EDT
Completed Phase 3 Interventional

Study to Evaluate SID 530 Compared to Taxotere

NCT00931008
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
SID530, Taxotere
Drug
Lead sponsor
SK Chemicals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Miami, Florida • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 6, 2026, 2:46 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

NCT00087178
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, adriamycin, epirubicin, fluorouracil
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
2,722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
586
States / cities
Huntsville, Alabama • Anchorage, Alaska • Glendale, Arizona + 396 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 6, 2026, 2:46 PM EDT
Completed No phase listed Observational

Role of 3D Tomography in Breast Cancer

NCT01090687
View directory record Official record
Conditions
Breast Cancer
Interventions
computed tomography (CT scan), computed tomography (CT scan)
Radiation · Device
Lead sponsor
University of Rochester
Other
Eligibility
40 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 6, 2026, 2:46 PM EDT
Not listed Phase 2 Interventional

ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer

NCT00404404
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, paclitaxel albumin-stabilized nanoparticle formulation
Biological · Drug
Lead sponsor
Premiere Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 6, 2026, 2:46 PM EDT
Completed No phase listed Observational

Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer

NCT04436393
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Guardant360 test
Diagnostic Test
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 6, 2026, 2:46 PM EDT
Recruiting Not applicable Interventional

Supporting Health Including Endocrine Treatment for Long Duration

NCT07482384
View directory record Official record
Conditions
Breast Cancer, Breast Cancer - Female, Breast Carcinoma, ER Positive Breast Cancer, PR-Positive Breast Cancer
Interventions
SHIELD portal
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 6, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

NCT00487786
View directory record Official record
Conditions
Neoplasms
Interventions
OGX-427, Docetaxel
Drug
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 6, 2026, 2:46 PM EDT
Completed Phase 2 Interventional

Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00005873
View directory record Official record
Conditions
Breast Cancer
Interventions
rubitecan
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Dublin, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 6, 2026, 2:46 PM EDT
Completed No phase listed Observational

A Pilot Study to Evaluate Nipple-Areolar Complex (NAC) Sparing Mastectomy

NCT00539227
View directory record Official record
Conditions
Breast Cancer
Interventions
NAC Sparing Mastectomy, Questionnaire
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Oct 6, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

NCT01434303
View directory record Official record
Conditions
HER2/Neu Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Entinostat, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Trastuzumab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 6, 2026, 2:46 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab Deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 6, 2026, 2:46 PM EDT